Comparison	O
of	O
the	O
Ex	O
Vivo	O
Expansion	O
of	O
UCB	O
-	O
Derived	O
CD34	B-GP
+	O
in	O
3D	O
DBM	O
/	O
MBA	O
Scaffolds	O
with	O
USSC	O
as	O
a	O
Feeder	O
Layer	O

Objective	O
(	O
s	O
):	O
Ex	O
vivo	O
expansion	O
of	O
hematopoitic	O
stem	O
cells	O
is	O
an	O
alternative	O
way	O
to	O
increase	O
umbilical	O
cord	O
blood	O
(	O
UCB	O
)-	O
CD34	B-GP
+	O
cells	O
for	O
bone	O
marrow	O
transplantation	O
.	O

For	O
this	O
purpose	O
demineralized	O
bone	O
matrix	O
(	O
DBM	O
)	O
and	O
mineralized	O
bone	O
allograft	O
(	O
MBA	O
)	O
as	O
two	O
scaffolds	O
based	O
on	O
bone	O
matrix	O
and	O
stem	O
cell	O
niche	O
,	O
were	O
simultaneously	O
used	O
to	O
enhance	O
the	O
effect	O
of	O
human	B-OG
mesenchymal	O
progenitor	O
cells	O
(	O
MPCs	O
)	O
-	O
unrestricted	O
somatic	O
stem	O
cells	O
(	O
USSCs	O
)	O
-	O
as	O
a	O
feeder	O
layer	O
.	O

Materials	O
and	O
Methods	O
:	O
USSCs	O
were	O
isolated	O
and	O
characterized	O
by	O
morphological	O
and	O
immunological	O
analysis	O
then	O
seeded	O
on	O
both	O
scaffolds	O
as	O
a	O
feeder	O
layer	O
.	O

UCB	O
-	O
CD34	B-GP
+	O
were	O
isolated	O
by	O
MACS	O
method	O
and	O
were	O
co	O
-	O
culture	O
expanded	O
by	O
USSC	O
in	O
3D	O
and	O
2D	O
environments	O
.	O

After	O
3	O
weeks	O
expansion	O
,	O
cells	O
were	O
counted	O
and	O
were	O
assessed	O
by	O
karyotype	O
,	O
flow	O
cytometry	O
,	O
clonogenic	O
activity	O
,	O
and	O
long	O
-	O
term	O
culture	O
-	O
initiating	O
cells	O
(	O
LTC	O
-	O
IC	O
).	O

Results	O
:	O
Co	O
-	O
culture	O
expansion	O
in	O
DBM	O
and	O
MBA	O
was	O
29	O
.	O
22	O
-	O
fold	O
and	O
27	O
.	O
77	O
-	O
fold	O
,	O
no	O
significant	O
differences	O
in	O
colony	O
and	O
LTC	O
-	O
IC	O
were	O
obtained	O
.	O

Maximum	O
number	O
of	O
colonies	O
belonged	O
to	O
the	O
day	O
14	O
with	O
the	O
73	O
%	O
CFU	O
-	O
GM	O
(	O
Colony	O
Forming	O
Unit	O
-	O
Granulocyte	O
/	O
Macrophage	O
)	O
in	O
contrast	O
to	O
the	O
day	O
0	O
which	O
was	O
BFU	O
-	O
E	O
/	O
CFU	O
-	O
E	O
(	O
Burst	O
/	O
Colony	O
Forming	O
Unit	O
-	O
Erythroid	O
).	O

Flow	O
cytometry	O
indicated	O
that	O
the	O
percentage	O
of	O
CD34	B-GP
+	O
marker	O
was	O
decreased	O
in	O
USSC	O
co	O
-	O
culture	O
and	O
the	O
highest	O
percentage	O
was	O
observed	O
in	O
simple	O
2D	O
culture	O
.	O

Conclusion	O
:	O
Because	O
of	O
acid	O
extraction	O
in	O
the	O
DBM	O
production	O
process	O
,	O
mineral	O
materials	O
were	O
removed	O
and	O
the	O
protein	O
background	O
that	O
was	O
more	O
flexible	O
was	O
presented	O
.	O

Therefore	O
these	O
results	O
suggest	O
that	O
USSC	O
-	O
DBM	O
can	O
be	O
a	O
suitable	O
ex	O
vivo	O
mimicry	O
niche	O
by	O
intensifying	O
of	O
surface	O
/	O
volume	O
ratio	O
and	O
supporting	O
the	O
stem	O
cell	O
differentiation	O
and	O
expansion	O
.	O

Introduction	O

Currently	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
is	O
considered	O
a	O
clinical	O
treatment	O
for	O
many	O
congenital	O
and	O
acquired	O
blood	B-DS
diseases	I-DS
(	O
1	O
).	O

For	O
this	O
treatment	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPCs	O
)	O
are	O
used	O
(	O
2	O
-	O
3	O
).	O

BMT	O
is	O
performed	O
either	O
as	O
an	O
autologous	O
or	O
an	O
allogeneic	O
transplantation	O
.	O

The	O
requirement	O
for	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
)	O
in	O
an	O
allogeneic	O
transplantation	O
is	O
100	O
,	O
000	O
times	O
greater	O
than	O
for	O
an	O
autologous	O
transplantation	O
(	O
4	O
).	O

There	O
are	O
three	O
sources	O
for	O
prior	O
HSCs	O
:	O
bone	O
marrow	O
,	O
peripheral	O
blood	O
and	O
cord	O
blood	O
.	O

Between	O
these	O
3	O
sources	O
,	O
cord	O
blood	O
sample	O
is	O
the	O
healthy	O
and	O
safe	O
source	O
of	O
HPC	O
cells	O
for	O
the	O
recipient	O
(	O
5	O
,	O
6	O
).	O

But	O
on	O
the	O
other	O
hand	O
the	O
total	O
number	O
of	O
cells	O
derived	O
from	O
umbilical	O
cord	O
blood	O
(	O
UCB	O
)	O
was	O
low	O
and	O
this	O
is	O
an	O
important	O
barrier	O
.	O

In	O
adult	O
recipients	O
,	O
BMT	O
is	O
limited	O
mainly	O
by	O
a	O
low	O
CD34	B-GP
+	O
cell	O
dose	O
(	O
7	O
).	O

To	O
overcome	O
this	O
problem	O
,	O
CD34	B-GP
+	O
expansion	O
is	O
recommended	O
(	O
8	O
).	O

Therefore	O
UCB	O
CD34	B-GP
+	O
cells	O
were	O
ex	O
vivo	O
expanded	O
and	O
then	O
injected	O
into	O
the	O
patient	O
to	O
replicate	O
(	O
9	O
).	O

In	O
nature	O
,	O
HSCs	O
are	O
in	O
the	O
microenvironment	O
,	O
or	O
niche	O
,	O
such	O
that	O
they	O
are	O
surrounded	O
by	O
stromal	O
and	O
mesenchymal	O
cells	O
.	O

The	O
niche	O
can	O
control	O
the	O
number	O
of	O
stem	O
cells	O
in	O
the	O
body	O
and	O
prevent	O
them	O
from	O
multiplying	O
too	O
.	O

Interaction	O
between	O
the	O
stem	O
cell	O
and	O
spatial	O
position	O
in	O
the	O
niche	O
establish	O
its	O
equilibrium	O
to	O
proliferation	O
or	O
differentiation	O
(	O
10	O
,	O
11	O
).	O

Stem	O
cells	O
(	O
SCs	O
)	O
cannot	O
survive	O
for	O
long	O
outside	O
the	O
niche	O
(	O
12	O
).	O
Ex	O
vivo	O
-	O
like	O
conditions	O
are	O
composed	O
of	O
a	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
structure	O
(	O
scaffold	O
)	O
and	O
a	O
feeder	O
layer	O
.	O

Scaffolding	O
features	O
are	O
similar	O
to	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
).	O

ECM	O
has	O
an	O
important	O
role	O
in	O
physical	O
and	O
chemical	O
signals	O
that	O
are	O
amplified	O
.	O

The	O
3D	O
environment	O
for	O
HSC	O
niche	O
with	O
helper	O
cells	O
is	O
associated	O
with	O
the	O
basal	O
material	O
.	O

In	O
3D	O
cultures	O
,	O
cells	O
are	O
grown	O
in	O
a	O
type	O
of	O
in	O
vivo	O
-	O
like	O
morphology	O
and	O
the	O
interaction	O
between	O
them	O
can	O
be	O
done	O
better	O
.	O

Three	O
dimensional	O
cultures	O
in	O
tissue	O
engineering	O
research	O
by	O
using	O
biochemical	O
materials	O
as	O
the	O
scaffold	O
is	O
rapidly	O
growing	O
.	O

3D	O
structures	O
in	O
tissue	O
engineering	O
is	O
a	O
multidisciplinary	O
field	O
and	O
is	O
a	O
new	O
and	O
exciting	O
technique	O
.	O

It	O
has	O
the	O
potential	O
to	O
create	O
organs	O
and	O
tissues	O
de	O
novo	O
(	O
13	O
).	O

It	O
involves	O
the	O
in	O
vitro	O
seeding	O
and	O
attachment	O
of	O
human	B-OG
cells	O
onto	O
the	O
scaffold	O
.	O

These	O
cells	O
then	O
proliferate	O
,	O
migrate	O
and	O
differentiate	O
into	O
the	O
specific	O
tissue	O
while	O
secreting	O
the	O
extracellular	O
matrix	O
components	O
required	O
for	O
creating	O
the	O
tissue	O
.	O

These	O
scaffolds	O
have	O
some	O
major	O
properties	O
:	O
They	O
are	O
biocompatible	O
,	O
injectable	O
and	O
biodegradable	O
(	O
14	O
).	O

The	O
3D	O
structure	O
is	O
used	O
for	O
providing	O
increased	O
surface	O
/	O
volume	O
ratio	O
of	O
culture	O
.	O

These	O
factors	O
let	O
the	O
scaffold	O
improve	O
the	O
efficiency	O
of	O
the	O
culture	O
.	O

Scaffolds	O
are	O
critical	O
,	O
both	O
ex	O
vivo	O
as	O
well	O
as	O
in	O
vivo	O
,	O
to	O
mimic	O
the	O
in	O
vivo	O
milieu	O
and	O
allow	O
cells	O
to	O
influence	O
their	O
own	O
microenvironments	O
.	O

Here	O
,	O
we	O
try	O
to	O
imitate	O
HSC	O
microenvironment	O
or	O
niche	O
in	O
3D	O
culture	O
.	O

For	O
bone	O
marrow	O
and	O
cartilage	O
,	O
the	O
most	O
commonly	O
used	O
scaffolds	O
are	O
MBA	O
(	O
mineralized	O
bone	O
allograft	O
)	O
and	O
DBM	O
(	O
de	O
-	O
mineralized	O
bone	O
matrix	O
)	O
(	O
15	O
).	O

Basically	O
,	O
they	O
are	O
used	O
for	O
repair	O
,	O
clinical	O
surgery	O
,	O
bone	O
allograft	O
and	O
transplantation	O
(	O
16	O
).	O

These	O
are	O
based	O
on	O
the	O
bone	O
matrix	O
but	O
the	O
only	O
difference	O
between	O
them	O
is	O
the	O
lack	O
of	O
mineralized	O
materials	O
in	O
DBM	O
by	O
the	O
acid	O
extraction	O
method	O
(	O
17	O
).	O

As	O
described	O
above	O
,	O
to	O
provide	O
a	O
similar	O
environment	O
in	O
vitro	O
,	O
human	B-OG
cord	O
blood	O
as	O
a	O
novel	O
source	O
of	O
human	B-OG
mesenchymal	O
progenitor	O
cell	O
(	O
MPC	O
)	O
(	O
18	O
)	O
-	O
unrestricted	O
somatic	O
stem	O
cells	O
(	O
USSCs	O
)	O
-	O
was	O
integrated	O
in	O
an	O
attempt	O
to	O
use	O
as	O
a	O
feeder	O
layer	O
(	O
19	O
-	O
21	O
).	O

USSC	O
cells	O
on	O
the	O
MBA	O
and	O
DBM	O
scaffolds	O
are	O
same	O
as	O
the	O
matrix	O
for	O
UCB	O
-	O
CD34	B-GP
+	O
cell	O
growth	O
support	O
.	O

The	O
culture	O
system	O
appeared	O
to	O
provide	O
a	O
different	O
microenvironment	O
from	O
the	O
2D	O
flask	O
culture	O
and	O
might	O
be	O
used	O
as	O
an	O
alternative	O
model	O
for	O
hematopoiesis	O
.	O

Our	O
goal	O
then	O
,	O
understands	O
the	O
importance	O
of	O
the	O
presence	O
of	O
the	O
mineral	O
materials	O
for	O
the	O
expansion	O
of	O
HSCs	O
and	O
the	O
extent	O
of	O
the	O
influence	O
of	O
the	O
self	O
-	O
renewal	O
of	O
stem	O
cells	O
in	O
the	O
3D	O
culture	O
by	O
USSC	O
feeder	O
in	O
contrast	O
to	O
the	O
2D	O
culture	O
.	O

This	O
research	O
aims	O
to	O
increase	O
the	O
number	O
of	O
hematopoietic	O
stem	O
cells	O
with	O
minimal	O
genetic	O
manipulation	O
in	O
three	O
-	O
dimensional	O
culture	O
.	O

However	O
,	O
to	O
reduce	O
the	O
risk	O
of	O
rejection	O
minimal	O
genetic	O
manipulation	O
and	O
techniques	O
should	O
be	O
involved	O
.	O

Materials	O
and	O
Methods	O

Generation	O
and	O
expansion	O
of	O
USSCs	O
from	O
fresh	O
UCB	O

UCB	O
samples	O
were	O
collected	O
from	O
full	O
term	O
,	O
normal	O
deliveries	O
according	O
to	O
the	O
approved	O
ethical	O
procedures	O
at	O
Tarbiat	O
Modares	O
University	O
(	O
Iran	O
,	O
Tehran	O
,	O
Shariati	O
Hospital	O
).	O

From	O
each	O
donor	O
,	O
informed	O
consent	O
was	O
acquired	O
according	O
to	O
patient	O
sample	O
collection	O
for	O
research	O
studies	O
protocol	O
approved	O
by	O
the	O
ethics	O
committee	O
.	O

After	O
that	O
USSCs	O
were	O
isolated	O
according	O
to	O
a	O
protocol	O
by	O
Kogler	O
et	O
al	O
.	O

To	O
isolate	O
the	O
mononuclear	O
cells	O
(	O
MNCs	O
)	O
and	O
reduce	O
RBC	O
contamination	O
of	O
the	O
upper	O
phase	O
to	O
the	O
minimum	O
level	O
,	O
low	O
-	O
density	O
(	O
less	O
than	O
1	O
.	O
077	O
g	O
/	O
ml	O
)	O
cell	O
isolation	O
was	O
performed	O
by	O
Ficoll	O
-	O
Hypaque	O
gradient	O
centrifugation	O
(	O
Pharmacia	O
,	O
Uppsala	O
,	O
Sweden	O
).	O

After	O
2	O
washes	O
by	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
),	O
cells	O
were	O
cultured	O
in	O
T25	O
flasks	O
and	O
specific	O
media	O
:	O
low	O
-	O
glucose	O
DMEM	O
supplemented	O
with	O
10	O
-	O
7	O
M	O
Dexamethasone	O
,	O
30	O
%	O
FCS	O
,	O
2	O
mM	O
ultraglutamine	O
,	O
100U	O
/	O
ml	O
penicillin	O
G	O
,	O
100	O
µg	O
/	O
ml	O
streptomycin	O
,	O
it	O
will	O
be	O
better	O
by	O
used	O
of	O
Myelocult	O
medium	O
containing	O
12	O
.	O
5	O
%	O
FCS	O
and	O
12	O
.	O
5	O
%	O
horse	B-OG
serum	O
.	O

Cells	O
were	O
incubated	O
at	O
37	O
°	O
C	O
in	O
5	O
%	O
CO2	O
in	O
a	O
fully	O
humidified	O
.	O

After	O
two	O
weeks	O
the	O
adherent	O
USSC	O
colonies	O
were	O
observed	O
.	O

Monoclonal	O
antibodies	B-GP
for	O
immunophenotyping	O
of	O
USSCs	O

Fluorescein	O
isothiocyanate	O
-	O
conjugated	O
antibodies	B-GP
(	O
Abs	B-GP
)	O
were	O
obtained	O
as	O
follows	O
:	O
USSC	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
assay	O
to	O
detect	O
their	O
markers	O
.	O

These	O
cells	O
were	O
positive	O
for	O
CD166	B-GP
,	O
CD73	B-GP
,	O
CD105	B-GP
,	O
CD90	B-GP
,	O
CD44	B-GP
,	O
weak	O
positive	O
expression	O
for	O
KDR	B-GP
,	O
and	O
negative	O
for	O
CD117	B-GP
,	O
CD34	B-GP
,	O
CD45	B-GP
and	O
Cadherin	B-GP
V	I-GP
.	O

Transdifferentiation	O
of	O
USSCs	O
into	O
adipocytes	O
and	O
osteoblasts	O

In	O
order	O
to	O
confirm	O
the	O
source	O
USSCs	O
as	O
the	O
human	B-OG
mesenchymal	O
progenitor	O
cells	O
,	O
and	O
the	O
process	O
of	O
differentiation	O
,	O
we	O
check	O
differentiation	O
potential	O
of	O
USSC	O
cells	O
.	O

For	O
osteogenic	O
differentiation	O
,	O
the	O
cultured	O
cells	O
were	O
incubated	O
in	O
osteogenic	O
medium	O
containing	O
DMEM	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
β	O
-	O
glycerol	O
phosphate	O
10	O
mM	O
,	O
dexamethasone	O
10	O
-	O
7M	O
,	O
and	O
ascorbic	O
acid	O
bi	O
-	O
phosphate	O
50	O
µg	O
/	O
ml	O
(	O
Sigma	O
).	O

The	O
culture	O
media	O
were	O
changed	O
twice	O
a	O
week	O
for	O
3	O
weeks	O
.	O

Afterwards	O
,	O
cells	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
for	O
20	O
min	O
,	O
washed	O
with	O
PBS	O
and	O
stained	O
with	O
Alizarin	O
-	O
Red	O
solution	O
(	O
in	O
60	O
%	O
isopropanol	O
)	O
for	O
10	O
min	O
,	O
followed	O
by	O
repeated	O
washings	O
.	O

To	O
induce	O
adipocyte	O
differentiation	O
,	O
USSCs	O
were	O
cultured	O
in	O
DMEM	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
dexamethasone	O
250	O
nM	O
,	O
insulin	O
66nM	O
,	O
isobutyl	O
-	O
methylxanthine	O
0	O
.	O
5	O
mM	O
,	O
and	O
indomethacine	O
0	O
.	O
2mM	O
for	O
3	O
weeks	O
and	O
also	O
for	O
specific	O
staining	O
,	O
cells	O
were	O
fixed	O
and	O
incubated	O
with	O
Oil	O
-	O
Red	O
.	O

USSCs	O
were	O
cultured	O
as	O
a	O
feeder	O
layer	O

These	O
isolated	O
cells	O
were	O
cultured	O
on	O
a	O
48	O
-	O
well	O
plate	O
.	O

When	O
the	O
cells	O
reached	O
80	O
%	O
confluence	O
,	O
their	O
mitotic	O
activity	O
was	O
disabled	O
by	O
Mitomycin	O
-	O
C	O
10	O
µg	O
/	O
ml	O
(	O
Sigma	O
)	O
according	O
to	O
its	O
protocol	O
:	O
culture	O
media	O
was	O
removed	O
and	O
cells	O
were	O
incubated	O
by	O
mitomycin	O
-	O
C	O
for	O
2	O
hours	O
.	O

After	O
incubation	O
time	O
it	O
was	O
washed	O
2	O
times	O
by	O
PBS	O
and	O
fresh	O
media	O
was	O
added	O
.	O

For	O
3D	O
culture	O
,	O
these	O
cells	O
should	O
seed	O
on	O
the	O
scaffolds	O
.	O

First	O
MBA	O
and	O
DBM	O
slices	O
were	O
cut	O
to	O
the	O
desired	O
size	O
(	O
6	O
to	O
8	O
mm	O
sided	O
cubic	O
pieces	O
)	O
by	O
the	O
sterile	O
scalpel	O
.	O

Then	O
the	O
surfaces	O
of	O
the	O
scaffolds	O
were	O
prepared	O
.	O

To	O
prepare	O
and	O
dispose	O
,	O
they	O
were	O
immersed	O
overnight	O
in	O
the	O
PBS	O
with	O
gelatin	O
0	O
.	O
1	O
%	O
which	O
opens	O
the	O
pores	O
like	O
a	O
spongy	O
tissue	O
,	O
ready	O
to	O
work	O
.	O

Afterwards	O
,	O
nearly	O
3	O
×	O
106	O
USSC	O
cells	O
from	O
three	O
T75	O
culture	O
flasks	O
were	O
removed	O
by	O
the	O
trypsin	B-GP
0	O
.	O
25	O
%	O
(	O
GIBCO	O
).	O

This	O
number	O
of	O
cells	O
in	O
the	O
DMEM	O
media	O
supplemented	O
by	O
30	O
%	O
FBS	O
were	O
added	O
to	O
MBA	O
and	O
DBM	O
scaffolds	O
(	O
9	O
pieces	O
each	O
).	O

This	O
concentrated	O
cell	O
suspension	O
was	O
rotating	O
for	O
8	O
hours	O
during	O
the	O
incubation	O
.	O

After	O
this	O
time	O
the	O
media	O
was	O
replaced	O
by	O
fresh	O
DMEM	O
.	O

This	O
rotation	O
is	O
needed	O
to	O
push	O
the	O
cells	O
into	O
the	O
pores	O
of	O
the	O
scaffolds	O
.	O

After	O
3	O
days	O
,	O
this	O
feeder	O
layer	O
can	O
be	O
disabled	O
by	O
Mitomycin	O
-	O
C	O
too	O
.	O

These	O
scaffolds	O
were	O
placed	O
in	O
18	O
wells	O
of	O
a	O
48	O
well	O
plate	O
that	O
were	O
previously	O
coated	O
with	O
a	O
USSC	O
feeder	O
layer	O
(	O
9	O
wells	O
for	O
DBM	O
and	O
9	O
wells	O
for	O
MBA	O
).	O

Scanning	O
e	O
lectron	O
m	O
icroscope	O
(	O
SEM	O
)	O

For	O
SEM	O
imaging	O
,	O
we	O
should	O
choose	O
a	O
process	O
that	O
preserves	O
the	O
structure	O
of	O
freshly	O
killed	O
material	O
in	O
a	O
state	O
that	O
most	O
closely	O
resembles	O
the	O
structure	O
and	O
/	O
or	O
composition	O
of	O
the	O
original	O
living	O
state	O
.	O

For	O
chemical	O
fixation	O
as	O
the	O
non	O
-	O
coagulative	O
process	O
,	O
we	O
need	O
paraformaldehyde	O
4	O
%.	O

In	O
this	O
process	O
,	O
first	O
the	O
culture	O
media	O
was	O
removed	O
,	O
and	O
fixed	O
in	O
paraformaldehyde	O
(	O
pH	O
7	O
)	O
at	O
4oC	O
for	O
20	O
min	O
.	O
the	O
scaffold	O
samples	O
were	O
then	O
dehydrated	O
through	O
a	O
graded	O
ethanol	O
series	O
and	O
ultra	O
-	O
structurally	O
scoped	O
using	O
an	O
electron	O
microscope	O
(	O
Philips	O
).	O

HSC	O
isolation	O
by	O
MACS	O
(	O
m	O
agnetic	O
a	O
ctivated	O
c	O
ell	O
s	O
orting	O
)	O
method	O

MNCs	O
were	O
isolated	O
as	O
described	O
above	O
,	O
and	O
then	O
the	O
CD34	B-GP
+	O
cells	O
were	O
isolated	O
from	O
this	O
MNC	O
population	O
,	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
for	O
the	O
CD34	B-GP
cell	O
isolation	O
kit	O
(	O
Miltenyi	O
Biotech	O
,	O
BergischGladbach	O
,	O
Germany	O
).	O

The	O
cell	O
suspension	O
was	O
adjacent	O
by	O
blocking	O
agent	O
and	O
an	O
antibody	B-GP
labeled	O
with	O
a	O
magnet	O
to	O
one	O
hr	O
at	O
4	O
°	O
C	O
and	O
dark	O
place	O
.	O

This	O
antibody	B-GP
was	O
against	O
CD34	B-GP
marker	O
.	O

After	O
this	O
period	O
,	O
samples	O
were	O
washed	O
with	O
EDTA	O
-	O
PBS	O
buffer	O
.	O

Afterwards	O
,	O
the	O
suspension	O
was	O
passed	O
through	O
the	O
LS	O
separation	O
columns	O
(	O
Miltenyi	O
Biotech	O
,	O
BergischGladbach	O
,	O
Germany	O
)	O
and	O
eventually	O
with	O
the	O
help	O
of	O
the	O
piston	O
and	O
pressure	O
cells	O
,	O
CD34	B-GP
+	O
from	O
other	O
cord	O
blood	O
mononuclear	O
cells	O
were	O
separated	O
.	O

As	O
a	O
result	O
the	O
purity	O
of	O
CD34	B-GP
+	O
cells	O
ranged	O
from	O
85	O
to	O
95	O
%.	O

Ex	O
vivo	O
expansion	O
of	O
cord	O
blood	O
hematopoietic	O
cells	O

Isolated	O
hematopoietic	O
cells	O
were	O
then	O
cultured	O
in	O
StemSpan	O
(	O
Stemcell	O
Technologies	O
#	O
09600	O
)	O
containing	O
stem	B-GP
cell	I-GP
factor	I-GP
(	O
SCF	B-GP
)	O
100	O
ng	O
/	O
mL	O
and	O
FMS	B-GP
-	I-GP
like	I-GP
tyrosine	I-GP
kinase	I-GP
-	I-GP
3	I-GP
100	O
ng	O
/	O
ml	O
,	O
and	O
100	O
ng	O
/	O
mL	O
thrombopoietin	B-GP
.	O

They	O
were	O
separated	O
and	O
cultured	O
in	O
48	O
well	O
plates	O
in	O
four	O
culture	O
conditions	O
:	O
first	O
in	O
2D	O
culture	O
(	O
without	O
feeder	O
layer	O
and	O
scaffolds	O
)	O
that	O
is	O
simple	O
2D	O
culture	O
(	O
S2D	O
),	O
second	O
in	O
2D	O
culture	O
with	O
the	O
USSCs	O
as	O
a	O
feeder	O
layer	O
(	O
F2D	O
),	O
third	O
in	O
3D	O
culture	O
(	O
DBM	O
scaffold	O
accompanied	O
by	O
USSC	O
feeder	O
layer	O
)	O
and	O
fourth	O
in	O
3D	O
culture	O
again	O
(	O
MBA	O
scaffold	O
accompanied	O
by	O
USSC	O
feeder	O
layer	O
).	O

In	O
every	O
condition	O
they	O
were	O
cultured	O
in	O
9	O
wells	O
of	O
48	O
-	O
well	O
plates	O
.	O

These	O
9	O
wells	O
were	O
counted	O
within	O
3	O
weeks	O
expansion	O
and	O
were	O
done	O
triplicate	O
per	O
week	O
.	O

Flow	O
cytometry	O

Hematopoietic	O
cells	O
were	O
analyzed	O
before	O
and	O
after	O
3	O
weeks	O
ex	O
vivo	O
expansion	O
by	O
two	O
-	O
color	O
ﬂow	O
cytometry	O
(	O
PARTEC	O
,	O
Germany	O
).	O

Nearly	O
105	O
cells	O
were	O
re	O
-	O
suspended	O
in	O
PBS	O
-	O
5	O
%	O
FBS	O
and	O
were	O
stained	O
with	O
ﬂuorescein	O
isothiocyanate	O
(	O
FITC	O
)-	O
conjugated	O
anti	O
-	O
human	B-OG
CD34	B-GP
.	O

These	O
cells	O
were	O
gated	O
with	O
low	O
side	O
scatter	O
.	O

In	O
order	O
to	O
confirm	O
the	O
speciﬁcity	O
of	O
staining	O
,	O
we	O
stained	O
hematopoietic	O
cells	O
by	O
an	O
isotype	O
control	O
with	O
FITC	O
-	O
mouse	B-OG
IgG1	B-GP
in	O
a	O
replicate	O
manner	O
to	O
ensure	O
the	O
speciﬁcity	O
of	O
staining	O
.	O

Acquired	O
data	O
using	O
PARTEC	O
ﬂow	O
cytometer	O
were	O
then	O
analyzed	O
by	O
FloMax	O
software	O
.	O

Clonogenic	O
assay	O

In	O
the	O
isolation	O
day	O
and	O
at	O
the	O
end	O
of	O
1st	O
,	O
2nd	O
and	O
3rd	O
weeks	O
for	O
all	O
3	O
groups	O
,	O
we	O
prepared	O
three	O
dilutions	O
of	O
expanded	O
cells	O
500	O
,	O
1000	O
,	O
1500	O
per	O
each	O
culture	O
condition	O
.	O

Every	O
cell	O
dilution	O
was	O
mixed	O
with	O
1	O
ml	O
of	O
Methocult	O
™	O
GF	O
+	O
H4435	O
methylcellulose	O
medium	O
(	O
Stemcell	O
Technologies	O
#	O
04435	O
)	O
in	O
separate	O
tubes	O
,	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
,	O
the	O
contents	O
of	O
each	O
tube	O
were	O
plated	O
within	O
separate	O
wells	O
of	O
6	O
-	O
well	O
plates	O
.	O

Plates	O
were	O
incubated	O
at	O
37	O
°	O
C	O
with	O
more	O
than	O
95	O
%	O
humidity	O
and	O
5	O
%	O
CO2	O
for	O
2	O
weeks	O
.	O

To	O
maintain	O
culture	O
humidity	O
,	O
one	O
well	O
was	O
filled	O
with	O
sterile	O
water	O
.	O

USSC	O
cells	O
in	O
the	O
specific	O
media	O
.	O
A	O
)	O
USSC	O
colonies	O
after	O
2	O
weeks	O
.	O
B	O
)	O
USSC	O
cells	O
by	O
80	O
%	O
confluency	O

Long	O
-	O
term	O
culture	O
-	O
initiating	O
cells	O
(	O
LTC	O
-	O
IC	O
)	O

LTC	O
-	O
IC	O
assay	O
was	O
performed	O
according	O
to	O
the	O
technique	O
described	O
below	O
.	O
Bone	O
marrow	O
cells	O
were	O
cultivated	O
as	O
feeder	O
-	O
layer	O
cells	O
in	O
96	O
-	O
well	O
plate	O
format	O
.	O

These	O
cells	O
were	O
harvested	O
and	O
incubated	O
with	O
mitomycin	O
-	O
C	O
.	O

A	O
day	O
later	O
,	O
the	O
stromal	O
layers	O
were	O
charged	O
with	O
CD34	B-GP
+	O
cells	O
in	O
the	O
specific	O
Myelocult	O
medium	O
(	O
Stemcell	O
Technologies	O
#	O
05100	O
)	O
containing	O
10	O
−	O
6M	O
hydrocortisone	O
(	O
Stem	O
Cell	O
Technologies	O
#	O
07904	O
).	O

A	O
minimum	O
of	O
1	O
l03	O
up	O
to	O
a	O
maximum	O
of	O
4	O
×	O
l03	O
expanded	O
hematopoietic	O
cells	O
per	O
well	O
were	O
plated	O
.	O

After	O
5	O
weeks	O
of	O
incubation	O
,	O
cells	O
were	O
removed	O
and	O
assay	O
in	O
the	O
CFC	O
assay	O
as	O
described	O
above	O
.	O

A	O
well	O
is	O
scored	O
as	O
positive	O
if	O
one	O
or	O
more	O
BFU	O
-	O
E	O
,	O
CFU	O
-	O
GM	O
or	O
CFU	O
-	O
GEMM	O
is	O
detected	O
or	O
as	O
negative	O
if	O
no	O
colonies	O
are	O
present	O
.	O

The	O
LTC	O
-	O
IC	O
frequency	O
in	O
the	O
test	O
cell	O
population	O
is	O
calculated	O
from	O
the	O
proportion	O
of	O
negative	O
wells	O
(	O
no	O
CFC	O
present	O
)	O
and	O
the	O
method	O
of	O
maximum	O
likelihood	O
then	O
statistical	O
analysis	O
can	O
be	O
performed	O
.	O

Mitotic	O
chromosome	O
preparations	O
for	O
karyotyping	O

After	O
high	O
expansion	O
in	O
cell	O
count	O
,	O
the	O
cells	O
should	O
be	O
checked	O
for	O
chromosome	O
number	O
and	O
banding	O
pattern	O
to	O
determine	O
if	O
they	O
were	O
altered	O
from	O
the	O
normal	O
(	O
expected	O
)	O
pattern	O
.	O

For	O
harvesting	O
cells	O
,	O
at	O
first	O
0	O
.	O
15	O
ml	O
of	O
50	O
µg	O
/	O
ml	O
Colchicine	O
solution	O
was	O
added	O
to	O
each	O
culture	O
tube	O
containing	O
expanded	O
CD34	B-GP
+	O
cells	O
and	O
followed	O
by	O
incubation	O
at	O
37	O
°	O
C	O
and	O
centrifuge	O
.	O

Then	O
2	O
-	O
3	O
ml	O
of	O
prewarmed	O
0	O
.	O
075	O
M	O
KCl	O
solution	O
was	O
added	O
to	O
the	O
cell	O
pellet	O
which	O
after	O
10	O
min	O
centrifugation	O
at	O
500	O
×	O
g	O
,	O
were	O
gently	O
pipeted	O
by	O
fixative	O
solution	O
(	O
3	O
:	O
1	O
(	O
v	O
/	O
v	O
)	O
methanol	O
/	O
glacial	O
acetic	O
acid	O
)	O
followed	O
by	O
incubation	O
at	O
room	O
temperature	O
and	O
centrifuge	O
.	O

This	O
step	O
was	O
repeated	O
twice	O
more	O
by	O
applying	O
a	O
small	O
drop	O
of	O
cell	O
suspension	O
onto	O
the	O
surface	O
of	O
a	O
slide	O
and	O
allowing	O
it	O
to	O
spread	O
.	O

Slide	O
was	O
stained	O
by	O
Giemsa	O
solution	O
.	O

Statistical	O
analysis	O

Results	O
were	O
expressed	O
as	O
mean	O
±	O
SD	O
and	O
analyzed	O
by	O
the	O
T	O
test	O
.	O

Differences	O
were	O
considered	O
to	O
be	O
significant	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

Population	O
doubling	O
time	O
of	O
USSCs	O
cells	O
in	O
primary	O
culture	O
up	O
to	O
the	O
30	O
passages	O
.	O

Average	O
of	O
PDT	O
was	O
49	O
.	O
48	O
±	O
0	O
.	O
3	O
hr	O

Results	O

Cell	O
culture	O

USSC	O
colonies	O
were	O
observed	O
after	O
2	O
weeks	O
of	O
USSC	O
cell	O
culture	O
(	O
Figure	O
1A	O
).	O

After	O
each	O
passage	O
these	O
spindle	O
-	O
shaped	O
cells	O
reached	O
complete	O
confluency	O
(	O
Figure	O
1B	O
).	O

It	O
didn	O
’	O
t	O
take	O
longer	O
to	O
reach	O
confluency	O
and	O
their	O
morphology	O
didn	O
’	O
t	O
change	O
with	O
each	O
passage	O
.	O

The	O
results	O
related	O
to	O
the	O
PDT	O
(	O
population	O
doubling	O
time	O
)	O
in	O
different	O
passages	O
of	O
the	O
USSCs	O
are	O
shown	O
in	O
Figure	O
2	O
.	O

PDT	O
didn	O
’	O
t	O
change	O
during	O
the	O
experiment	O
periods	O
from	O
primary	O
culture	O
to	O
passage	O
30	O
.	O

Characterization	O
of	O
USSCs	O
by	O
flow	O
cytometry	O

USSCs	O
in	O
4th	O
passage	O
were	O
subjected	O
to	O
flow	O
cytometry	O
for	O
the	O
presence	O
or	O
absence	O
of	O
hematopoietic	O
and	O
endothelial	O
markers	O
.	O

USSCs	O
typically	O
expressed	O
the	O
surface	O
antigens	O
CD105	B-GP
,	O
CD44	B-GP
and	O
CD73	B-GP
(	O
Figure	O
3	O
),	O
and	O
showed	O
low	O
level	O
of	O
KDR	B-GP
but	O
were	O
negative	O
for	O
CD34	B-GP
and	O
CD45	B-GP
,	O
which	O
are	O
the	O
early	O
hematopoietic	O
markers	O
.	O

Analysis	O
of	O
cell	O
surface	O
markers	O
by	O
FACS	O
analysis	O
were	O
confirmed	O
these	O
isolated	O
cells	O
.	O

Differentiation	O
of	O
USSCs	O
to	O
osteogenic	O
and	O
adipogenic	O

USSC	O
cultures	O
in	O
adipogenic	O
differentiation	O
medium	O
after	O
2	O
weeks	O
,	O
presenting	O
fat	O
vacuoles	O
in	O
the	O
cytoplasm	O
can	O
be	O
appeared	O
by	O
oil	O
red	O
staining	O
(	O
Figure	O
4A	O
).	O

For	O
osteogenic	O
inductive	O
medium	O
,	O
appearance	O
of	O
refringent	O
crystals	O
were	O
be	O
observed	O
by	O
Alizarin	O
Red	O
staining	O
(	O
Figure	O
4B	O
).	O

Scanning	O
electron	O
microscope	O
views	O

About	O
40	O
%	O
of	O
scaffold	O
surface	O
pictures	O
showed	O
porosity	O
.	O
Figure	O
5	O
shows	O
the	O
surface	O
of	O
scaffolds	O
without	O
cells	O
as	O
the	O
control	O
,	O
so	O
that	O
very	O
small	O
pores	O
in	O
the	O
scaffold	O
can	O
be	O
seen	O
under	O
a	O
microscope	O
in	O
which	O
these	O
pores	O
are	O
so	O
deeply	O
dark	O
.	O

When	O
the	O
scaffolds	O
were	O
seeded	O
by	O
USSCs	O
as	O
the	O
feeder	O
layer	O
,	O
the	O
empty	O
scaffold	O
is	O
less	O
clear	O
.	O

Elongated	O
and	O
spindle	O
-	O
shaped	O
cells	O
covered	O
the	O
surface	O
but	O
few	O
of	O
these	O
surrounded	O
cells	O
entered	O
into	O
the	O
cavities	O
and	O
pores	O
.	O

Cells	O
were	O
more	O
coated	O
on	O
the	O
outer	O
face	O
.	O

Cell	O
size	O
was	O
about	O
100	O
µm	O
and	O
with	O
more	O
magnification	O
each	O
cell	O
could	O
be	O
observed	O
separately	O
as	O
a	O
light	O
band	O
.	O

However	O
,	O
with	O
the	O
same	O
zoom	O
level	O
on	O
the	O
control	O
scaffold	O
,	O
only	O
the	O
dark	O
face	O
without	O
the	O
light	O
bands	O
were	O
visible	O
(	O
Figure	O
5B	O
,	O
E	O
).	O

The	O
effect	O
of	O
USSC	O
and	O
scaffold	O
combination	O
on	O
the	O
expansion	O
of	O
UCB	O
-	O
CD34	B-GP
+	O
over	O
3	O
weeks	O
.	O

Values	O
are	O
expressed	O
as	O
mean	O
±	O
SD	O
for	O
3	O
numbers	O
of	O
experiments	O
.	O

Fold	O
expansion	O
was	O
calculated	O
based	O
on	O
the	O
cell	O
counts	O
(	O
1000	O
)	O
on	O
day	O
0	O

Total	O
Cells	O
(	O
fold	O
exp	O
.)	O

Groups	O

1st	O
wk	O

2nd	O
wk	O

3rd	O
wk	O

S2D	O
(	O
n	O
=	O
3	O
)	O

13800	O
±	O
1600	O
(	O
13	O
.	O
8	O
±	O
1	O
.	O
6	O
)	O

53400	O
±	O
3200	O
(	O
53	O
.	O
4	O
±	O
3	O
.	O
2	O
)	O

101900	O
±	O
8000	O
(	O
101	O
.	O
9	O
±	O
8	O
)	O

F2D	O
(	O
n	O
=	O
3	O
)	O

28700	O
±	O
3400	O
(	O
28	O
.	O
7	O
±	O
3	O
.	O
4	O
)	O

104300	O
±	O
11000	O
(	O
104	O
.	O
3	O
±	O
11	O
)	O

194200	O
±	O
4600	O
(	O
194	O
.	O
2	O
±	O
4	O
.	O
6	O
)	O

MBA	O
(	O
n	O
=	O
3	O
)	O

40800	O
±	O
4100	O
(	O
40	O
.	O
8	O
±	O
4	O
.	O
1	O
)	O

145500	O
±	O
5800	O
(	O
145	O
.	O
5	O
±	O
5	O
.	O
8	O
)	O

271700	O
±	O
13000	O
(	O
271	O
.	O
7	O
±	O
13	O
.	O
2	O
)	O

DBM	O
(	O
n	O
=	O
3	O
)	O

44200	O
±	O
1600	O
(	O
44	O
.	O
2	O
±	O
1	O
.	O
6	O
)	O

176700	O
±	O
6400	O
(	O
176	O
.	O
7	O
±	O
6	O
.	O
4	O
)	O

305800	O
±	O
12700	O
(	O
305	O
.	O
8	O
±	O
12	O
.	O
7	O
)	O

Abbreviation	O
:	O
simple	O
2D	O
culture	O
(	O
S2D	O
),	O
simple	O
2D	O
culture	O
with	O
feeder	O
(	O
F2D	O
),	O
mineralized	O
bone	O
allograft	O
(	O
MBA	O
),	O
de	O
-	O
mineralized	O
bone	O
matrix	O
(	O
DBM	O
)	O

Immunophenotypes	O
of	O
USSCs	O
.	O

USSC	O
preparations	O
were	O
labeled	O
with	O
the	O
monoclonal	O
Abs	B-GP
specific	O
for	O
the	O
molecule	O
indicated	O
(	O
filled	O
histograms	O
)	O
or	O
isotype	O
controls	O
(	O
open	O
histograms	O
).	O

USSC	O
are	O
positive	O
for	O
CD73	B-GP
,	O
CD44	B-GP
and	O
CD105	B-GP
but	O
have	O
weak	O
positive	O
expression	O
for	O
KDR	B-GP

Isolation	O
and	O
differentiation	O
characteristics	O
of	O
human	B-OG
UCB	O
-	O
derived	O
USSCs	O
.	O
A	O
)	O
The	O
results	O
of	O
Oil	O
Red	O
-	O
O	O
-	O
staining	O
in	O
differentiated	O
adipogenic	O
cells	O
.	O
B	O
)	O
Results	O
of	O
osteogenic	O
differentiation	O
by	O
Alizarin	O
Red	O
-	O
staining	O
.	O

Ex	O
vivo	O
expansion	O
of	O
cord	O
blood	O
hematopoietic	O
cells	O

UCB	O
CD34	B-GP
+	O
cells	O
were	O
seeded	O
at	O
a	O
concentration	O
of	O
1	O
×	O
103	O
cells	O
per	O
each	O
well	O
in	O
the	O
48	O
-	O
well	O
plate	O
in	O
the	O
hematopoietic	O
stem	O
cell	O
expansion	O
medium	O
(	O
StemSpan	O
supplemented	O
by	O
3	O
cocktail	O
cytokines	B-GP
:	O
Flt3	B-GP
-	I-GP
L	I-GP
,	O
SCF	B-GP
,	O
TPO	B-GP
).	O

CD34	B-GP
+	O
cells	O
in	O
4	O
groups	O
were	O
expanded	O
:	O
S2D	O
,	O
F2D	O
,	O
DBM	O
and	O
MBA	O
.	O

These	O
4	O
groups	O
were	O
counted	O
after	O
each	O
week	O
during	O
3	O
weeks	O
by	O
triplicate	O
for	O
each	O
group	O
.	O

The	O
result	O
is	O
shown	O
in	O
Table	O
1	O
.	O

In	O
F2D	O
culture	O
,	O
the	O
CD34	B-GP
+	O
cells	O
were	O
co	O
-	O
cultivated	O
on	O
the	O
USSC	O
-	O
feeder	O
layer	O
.	O

USSCs	O
showed	O
their	O
ability	O
to	O
support	O
the	O
expansion	O
of	O
CD34	B-GP
+	O
cells	O
over	O
three	O
weeks	O
(	O
Figure	O
6	O
).	O

The	O
highest	O
cell	O
count	O
was	O
in	O
3D	O
culture	O
but	O
DBM	O
was	O
a	O
little	O
more	O
than	O
MBA	O
.	O

The	O
total	O
cell	O
count	O
on	O
the	O
USSC	O
layer	O
in	O
DBM	O
culture	O
increased	O
within	O
the	O
21	O
-	O
day	O
period	O
,	O
it	O
was	O
44	O
.	O
2	O
-	O
fold	O
±	O
1	O
.	O
6	O
-	O
fold	O
after	O
7	O
days	O
,	O
176	O
.	O
7	O
-	O
fold	O
±	O
6	O
.	O
4	O
-	O
fold	O
after	O
14	O
days	O
,	O
and	O
305	O
.	O
8	O
-	O
fold	O
±	O
12	O
.	O
7	O
-	O
fold	O
after	O
21	O
days	O
.	O

SEM	O
views	O
of	O
scaffold	O
surface	O
in	O
black	O
and	O
white	O
version	O
.	O
A	O
-	O
B	O
)	O
empty	O
MBA	O
without	O
USSC	O
cells	O
.	O
C	O
)	O
MBA	O
with	O
seeded	O
USSC	O
.	O
D	O
-	O
E	O
)	O
empty	O
DBM	O
without	O
USSC	O
cells	O
.	O
F	O
)	O
DBM	O
with	O
seeded	O
USSC	O

The	O
effect	O
of	O
USSC	O
presence	O
as	O
the	O
feeder	O
layer	O
on	O
the	O
colony	O
formation	O
of	O
UCB	O
-	O
CD34	B-GP
+	O
over	O
3	O
weeks	O
.	O

CFC	O
counts	O
were	O
performed	O
from	O
the	O
expanding	O
cultures	O
at	O
days	O
0	O
,	O
7	O
,	O
14	O
,	O
and	O
21	O
.	O

The	O
results	O
are	O
expressed	O
as	O
mean	O
±	O
SD	O
for	O
total	O
cells	O
,	O
CFC	O
,	O
BFU	O
-	O
E	O
/	O
CFU	O
-	O
E	O
,	O
CFU	O
-	O
GM	O
,	O
and	O
CFU	O
-	O
mix	O

Total	O
cells	O

CFC	O
/	O
103	O
cells	O

BFU	O
/	O
CFU	O
-	O
E	O
/	O
103	O
cells	O

CFU	O
-	O
GM	O
/	O
103	O
cells	O

CFU	O
-	O
mix	O
/	O
103	O
cells	O

Day	O
0	O

1000	O

30	O
.	O
9	O
±	O
2	O
.	O
1	O

22	O
.	O
6	O
±	O
0	O
.	O
7	O

9	O
.	O
5	O
±	O
1	O
.	O
1	O

2	O
.	O
8	O
±	O
0	O
.	O
3	O

1st	O
week	O

F2D	O

28700	O

23	O
.	O
2	O
±	O
1	O
.	O
5	O

9	O
.	O
4	O
±	O
0	O
.	O
5	O

12	O
.	O
2	O
±	O
0	O
.	O
7	O

1	O
.	O
6	O
±	O
0	O
.	O
3	O

MBA	O

40800	O

16	O
.	O
0	O
±	O
1	O
.	O
8	O

6	O
.	O
1	O
±	O
0	O
.	O
3	O

7	O
.	O
3	O
±	O
1	O
.	O
1	O

1	O
.	O
0	O
±	O
0	O
.	O
4	O

DBM	O

44200	O

16	O
.	O
3	O
±	O
2	O
.	O
7	O

7	O
.	O
3	O
±	O
0	O
.	O
9	O

7	O
.	O
9	O
±	O
1	O
.	O
7	O

1	O
.	O
1	O
±	O
0	O
.	O
1	O

2nd	O
week	O

F2D	O

104300	O

35	O
.	O
6	O
±	O
1	O
.	O
8	O

8	O
.	O
8	O
±	O
1	O
.	O
2	O

26	O
.	O
2	O
±	O
0	O
.	O
6	O

0	O
.	O
6	O
±	O
0	O
.	O
0	O

MBA	O

145500	O

28	O
.	O
6	O
±	O
2	O
.	O
0	O

7	O
.	O
1	O
±	O
0	O
.	O
7	O

20	O
.	O
7	O
±	O
1	O
.	O
3	O

0	O
.	O
8	O
±	O
0	O
.	O
0	O

DBM	O

176700	O

30	O
.	O
1	O
±	O
3	O
.	O
3	O

7	O
.	O
9	O
±	O
2	O
.	O
1	O

21	O
.	O
9	O
±	O
0	O
.	O
8	O

1	O
.	O
9	O
±	O
0	O
.	O
4	O

3rd	O
week	O

F2D	O

194200	O

24	O
.	O
4	O
±	O
1	O
.	O
8	O

6	O
.	O
2	O
±	O
0	O
.	O
9	O

17	O
.	O
1	O
±	O
0	O
.	O
7	O

1	O
.	O
1	O
±	O
0	O
.	O
2	O

MBA	O

271700	O

22	O
.	O
5	O
±	O
1	O
.	O
4	O

3	O
.	O
1	O
±	O
0	O
.	O
6	O

17	O
.	O
9	O
±	O
0	O
.	O
5	O

1	O
.	O
5	O
±	O
0	O
.	O
3	O

DBM	O

305800	O

23	O
.	O
9	O
±	O
1	O
.	O
7	O

4	O
.	O
7	O
±	O
0	O
.	O
3	O

18	O
.	O
4	O
±	O
1	O
.	O
0	O

1	O
.	O
0	O
±	O
0	O
.	O
4	O

Abbreviation	O
:	O
simple	O
2D	O
culture	O
with	O
feeder	O
(	O
F2D	O
),	O
mineralized	O
bone	O
allograft	O
(	O
MBA	O
),	O
de	O
-	O
mineralized	O
bone	O
matrix	O
(	O
DBM	O
),	O
Colony	O
Forming	O
Count	O
(	O
CFC	O
),	O
Burst	O
Forming	O
Unit	O
/	O
Colony	O
Forming	O
Unit	O
-	O
Erythroid	O
(	O
BFU	O
/	O
CFU	O
-	O
E	O
),	O
Colony	O
Forming	O
Unit	O
-	O
Granulocyte	O
/	O
Macrophage	O
(	O
CFU	O
-	O
GM	O
),	O
Colony	O
Forming	O
Unit	O
-	O
mix	O
(	O
CFU	O
-	O
mix	O
)	O

Flow	O
cytometry	O

CD34	B-GP
+	O
cells	O
were	O
enriched	O
by	O
nearly	O
90	O
percent	O
(	O
Figure	O
7	O
)	O
and	O
subsequently	O
after	O
3	O
weeks	O
expansion	O
,	O
CD34	B-GP
+	O
cells	O
were	O
analyzed	O
by	O
FACS	O
method	O
to	O
observe	O
their	O
CD34	B-GP
marker	O
ratio	O
(	O
Figure	O
8	O
).	O

The	O
global	O
competition	O
indicated	O
that	O
the	O
lowest	O
CD34	B-GP
marker	O
belonged	O
to	O
the	O
3D	O
culture	O
(	O
8	O
.	O
6	O
%	O
and	O
9	O
.	O
2	O
%	O
respectively	O
for	O
DBM	O
and	O
MBA	O
).	O

But	O
no	O
significant	O
difference	O
was	O
observed	O
between	O
MBA	O
and	O
DBM	O
in	O
the	O
kind	O
of	O
3D	O
condition	O
.	O

The	O
highest	O
CD34	B-GP
marker	O
was	O
observed	O
in	O
S2D	O
culture	O
(	O
17	O
.	O
3	O
%)	O
and	O
finally	O
for	O
the	O
F2D	O
group	O
it	O
was	O
10	O
.	O
5	O
%.	O

Percent	O
drop	O
in	O
CD34	B-GP
+	O
cells	O
was	O
greater	O
in	O
the	O
three	O
-	O
dimensional	O
culture	O
.	O

This	O
problem	O
can	O
partly	O
explain	O
the	O
high	O
levels	O
of	O
secreted	O
factors	O
attributed	O
myeloid	O
line	O
distinction	O
,	O
such	O
as	O
GM	B-GP
-	I-GP
CSF	I-GP
,	O
M	B-GP
-	I-GP
CSF	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
11	I-GP
and	O
SCF	B-GP
.	O

Also	O
the	O
IL	B-GP
-	I-GP
1B	I-GP
factor	O
secretion	O
by	O
both	O
USSC	O
and	O
CD34	B-GP
+	O
cells	O
strongly	O
enhanced	O
the	O
G	B-GP
-	I-GP
CSF	I-GP
production	O
by	O
USSC	O
cells	O
leading	O
to	O
the	O
differentiation	O
of	O
CD34	B-GP
+	O
cells	O
into	O
a	O
specific	O
cell	O
line	O
.	O

This	O
low	O
percentage	O
in	O
contrast	O
to	O
the	O
highest	O
expansion	O
and	O
CD34	B-GP
+	O
count	O
in	O
3D	O
condition	O
can	O
be	O
ignored	O
.	O

On	O
the	O
first	O
day	O
we	O
charged	O
each	O
group	O
by	O
1000	O
cells	O
with	O
89	O
.	O
57	O
%	O
CD34	B-GP
+	O
cells	O
or	O
nearly	O
900	O
CD34	B-GP
+	O
cells	O
.	O

For	O
S2D	O
,	O
we	O
counted	O
101900	O
cells	O
by	O
17	O
.	O
3	O
%	O
or	O
about	O
17600	O
CD34	B-GP
+	O
cells	O
.	O

Therefore	O
fold	O
expansion	O
by	O
flow	O
cytometry	O
was	O
19	O
.	O
55	O
-	O
fold	O
±	O
1	O
.	O
5	O
-	O
fold	O
.	O

Other	O
HSCs	O
expansion	O
evaluation	O
by	O
flow	O
cytometry	O
is	O
shown	O
in	O
Figure	O
9	O
.	O

The	O
most	O
expansion	O
belonged	O
to	O
the	O
DBM	O
group	O
.	O

Colony	O
assay	O

Each	O
week	O
,	O
nonadherent	O
hematopoietic	O
cells	O
(	O
CD34	B-GP
+	O
cells	O
)	O
from	O
the	O
adherent	O
feeder	O
cells	O
were	O
separated	O
and	O
analyzed	O
by	O
CFC	O
to	O
evaluate	O
the	O
progenitor	O
content	O
and	O
CD34	B-GP
+	O
cells	O
.	O

As	O
summarized	O
in	O
Table	O
2	O
and	O
Figure	O
10	O
.	O

For	O
total	O
CFC	O
,	O
the	O
highest	O
CFC	O
expansion	O
was	O
observed	O
at	O
day	O
14	O
:	O
35	O
.	O
6	O
-	O
fold	O
±	O
1	O
.	O
8	O
-	O
fold	O
,	O
28	O
.	O
6	O
-	O
fold	O
±	O
2	O
.	O
0	O
-	O
fold	O
and	O
30	O
.	O
1	O
-	O
fold	O
±	O
3	O
.	O
3	O
-	O
fold	O
for	O
F2D	O
,	O
MBA	O
and	O
DBM	O
,	O
respectively	O
.	O

Similarly	O
,	O
amplification	O
of	O
CFU	O
-	O
GM	O
and	O
BFU	O
-	O
E	O
/	O
CFU	O
-	O
E	O
was	O
highest	O
,	O
whereas	O
CFC	O
was	O
reduced	O
after	O
2	O
weeks	O
.	O

The	O
composition	O
of	O
CFC	O
clearly	O
showed	O
that	O
after	O
2	O
weeks	O
about	O
73	O
%	O
of	O
colonies	O
obtained	O
were	O
CFU	O
-	O
GM	O
.	O

But	O
on	O
day	O
0	O
nearly	O
73	O
%	O
of	O
colonies	O
were	O
BFU	O
-	O
E	O
/	O
CFU	O
-	O
E	O
.	O

When	O
total	O
number	O
of	O
cells	O
generated	O
in	O
3D	O
culture	O
was	O
compared	O
to	O
2D	O
culture	O
,	O
significantly	O
higher	O
colony	O
counts	O
for	O
3D	O
were	O
determined	O
at	O
each	O
time	O
point	O
.	O

Because	O
these	O
colony	O
counts	O
were	O
in	O
1000	O
cells	O
,	O
so	O
that	O
in	O
comparison	O
with	O
total	O
cells	O
in	O
F2D	O
,	O
MBA	O
and	O
DBM	O
the	O
CFC	O
counts	O
were	O
3713	O
±	O
188	O
,	O
4161	O
±	O
291	O
and	O
5318	O
±	O
583	O
.	O

USSCs	O
co	O
-	O
cultivate	O
with	O
UCB	O
-	O
CD34	B-GP
+	O
over	O
1	O
A	O
),	O
2	O
B	O
),	O
and	O
3	O
C	O
)	O
weeks	O
expansion	O

The	O
frequency	O
of	O
long	O
-	O
term	O
culture	O
-	O
initiating	O
cells	O
in	O
different	O
condition	O
during	O
3	O
weeks	O
expansion	O

Frequency	O
of	O
LTC	O
-	O
IC	O
cells	O

Day	O
0	O

1	O
in	O
8372	O

1st	O
wk	O

2nd	O
wk	O

3rd	O
wk	O

S2D	O

1	O
in	O
11634	O

S2D	O

1	O
in	O
14840	O

S2D	O

1	O
in	O
22478	O

F2D	O

1	O
in	O
7389	O

F2D	O

1	O
in	O
5125	O

F2D	O

1	O
in	O
11650	O

MBA	O

1	O
in	O
7760	O

MBA	O

1	O
in	O
6192	O

MBA	O

1	O
in	O
13289	O

DBM	O

1	O
in	O
7554	O

DBM	O

1	O
in	O
5992	O

DBM	O

1	O
in	O
12673	O

Abbreviation	O
:	O
simple	O
2D	O
culture	O
(	O
S2D	O
),	O
simple	O
2D	O
culture	O
with	O
feeder	O
(	O
F2D	O
),	O
mineralized	O
bone	O
allograft	O
(	O
MBA	O
),	O
de	O
-	O
mineralized	O
bone	O
matrix	O
(	O
DBM	O
)	O

A	O
)	O
enumeration	O
of	O
CD34	B-GP
+	O
at	O
isolation	O
day	O
was	O
89	O
.	O
57	O
percentage	O
.	O
B	O
)	O
CD34	B-GP
+	O
cells	O
were	O
labeled	O
with	O
FITC	O
-	O
conjugated	O
antibody	B-GP
and	O
B	O
)	O
with	O
IgG1	B-GP
as	O
the	O
control	O
antibody	B-GP

LTC	O
-	O
IC	O

After	O
3	O
weeks	O
co	O
-	O
cultivation	O
of	O
CD34	B-GP
+	O
cells	O
on	O
the	O
USSC	O
layer	O
(	O
2D	O
and	O
3D	O
conditions	O
)	O
no	O
significant	O
differentiation	O
between	O
them	O
was	O
observed	O
in	O
contrast	O
to	O
the	O
simple	O
2D	O
culture	O
where	O
the	O
total	O
number	O
of	O
long	O
-	O
term	O
culture	O
-	O
initiating	O
cells	O
dropped	O
after	O
each	O
week	O
(	O
Table	O
3	O
).	O

The	O
culture	O
by	O
feeder	O
(	O
F2D	O
,	O
MBA	O
and	O
DBM	O
)	O
could	O
make	O
an	O
expansion	O
in	O
1	O
.	O
13	O
-	O
fold	O
,	O
1	O
.	O
07	O
-	O
fold	O
and	O
1	O
.	O
10	O
-	O
fold	O
in	O
the	O
first	O
week	O
and	O
also	O
in	O
1	O
.	O
63	O
-	O
fold	O
,	O
1	O
.	O
35	O
-	O
fold	O
and	O
1	O
.	O
39	O
-	O
fold	O
in	O
the	O
second	O
week	O
in	O
contrast	O
to	O
the	O
day	O
0	O
.	O

But	O
in	O
the	O
3rd	O
week	O
this	O
expansion	O
dropped	O
and	O
maintaining	O
of	O
LTC	O
-	O
IC	O
cells	O
reached	O
nearly	O
0	O
.	O
6	O
-	O
fold	O
.	O

Therefore	O
USSC	O
cells	O
could	O
only	O
preserve	O
the	O
hematopoietic	O
initiating	O
cells	O
just	O
for	O
2	O
weeks	O
in	O
the	O
ex	O
vivo	O
condition	O
and	O
make	O
long	O
term	O
hematopoesis	O
.	O

Karyotyping	O

For	O
research	O
in	O
genetics	O
and	O
cytogenetics	O
,	O
Karyotyping	O
was	O
developed	O
.	O

The	O
G	O
-	O
banded	O
karyotype	O
is	O
useful	O
in	O
the	O
identification	O
of	O
aberrant	O
chromosomes	O
and	O
absent	O
,	O
additional	O
,	O
or	O
aberrant	O
chromosomes	O
,	O
which	O
can	O
include	O
deletions	O
,	O
inversions	O
,	O
reciprocal	O
translocations	O
,	O
duplications	O
,	O
insertions	O
,	O
and	O
Robertsonian	O
chromosomes	O
.	O

Figure	O
11	O
shows	O
the	O
G	O
banding	O
pattern	O
in	O
normal	O
chromosomes	O
.	O

No	O
aberrations	O
were	O
obtained	O
and	O
did	O
not	O
alter	O
the	O
normal	O
banding	O
pattern	O
.	O

The	O
human	B-OG
karyotype	O
contains	O
22	O
autosomal	O
pairs	O
and	O
two	O
sex	O
chromosomes	O
.	O

The	O
female	O
karyotypes	O
contain	O
two	O
large	O
X	O
chromosomes	O
(	O
the	O
inactive	O
X	O
may	O
be	O
very	O
darkly	O
stained	O
),	O
whereas	O
the	O
male	O
karyotypes	O
contain	O
one	O
large	O
X	O
chromosome	O
and	O
a	O
small	O
one	O
.	O

Normal	O
karyotype	O
of	O
the	O
expanded	O
CD34	B-GP
+	O
cells	O
after	O
21	O
days	O
in	O
3D	O
DBM	O
condition	O
by	O
305	O
.	O
8	O
-	O
fold	O
expansion	O
was	O
obtained	O
.	O

Chromosome	O
count	O
was	O
46	O
as	O
in	O
normal	O
cells	O
and	O
no	O
abnormalities	O
in	O
quantity	O
(	O
aneuploidy	O
)	O
or	O
quality	O
were	O
observed	O
and	O
no	O
fusion	O
between	O
stromal	O
and	O
HSCs	O
occurred	O
.	O

The	O
CD34	B-GP
+	O
stem	O
cell	O
populations	O
after	O
3	O
weeks	O
ex	O
vivo	O
expansion	O
were	O
evaluated	O
by	O
means	O
of	O
flow	O
cytometry	O
.	O

Flow	O
cytometry	O
assay	O
showed	O
that	O
18	O
.	O
3	O
%	O
for	O
S2D	O
A	O
),	O
11	O
.	O
5	O
%	O
for	O
F2D	O
B	O
),	O
8	O
.	O
2	O
%	O
for	O
MBA	O
C	O
)	O
and	O
7	O
.	O
6	O
%	O
for	O
DBM	O
D	O
)	O

Discussion	O

In	O
previous	O
studies	O
,	O
at	O
first	O
,	O
nutritious	O
feeder	O
layer	O
(	O
mesenchymal	O
stem	O
cells	O
)	O
was	O
used	O
for	O
cell	O
proliferation	O
as	O
the	O
Dexter	O
culture	O
(	O
1977	O
).	O

But	O
Miller	O
showed	O
that	O
growth	O
factors	O
can	O
also	O
create	O
a	O
similar	O
environment	O
for	O
expansion	O
(	O
22	O
).	O

The	O
nutrients	O
and	O
growth	O
factors	O
layer	O
,	O
for	O
cell	O
proliferation	O
of	O
SCID	O
/	O
NOD	O
were	O
used	O
simultaneously	O
(	O
23	O
).	O

But	O
they	O
also	O
understood	O
that	O
over	O
a	O
long	O
period	O
of	O
time	O
,	O
this	O
environment	O
cannot	O
provide	O
reliable	O
cell	O
(	O
24	O
)	O
and	O
showed	O
that	O
stem	O
cells	O
are	O
sensitive	O
to	O
their	O
microenvironment	O
.	O

Here	O
the	O
porous	O
tantalum	O
scaffold	O
(	O
tantalum	O
-	O
coated	O
porous	O
biomaterial	O
(	O
TCPB	O
)),	O
only	O
after	O
a	O
week	O
,	O
showed	O
1	O
.	O
5	O
increasing	O
fold	O
compared	O
with	O
the	O
two	O
-	O
dimensional	O
culture	O
(	O
25	O
).	O

In	O
this	O
regard	O
,	O
the	O
engineering	O
matrices	O
and	O
other	O
polymer	O
or	O
nanomer	O
materials	O
were	O
used	O
(	O
26	O
-	O
31	O
).	O

The	O
result	O
of	O
these	O
experiments	O
for	O
replication	O
(	O
32	O
-	O
34	O
)	O
or	O
differentiation	O
(	O
35	O
)	O
of	O
stem	O
cells	O
was	O
performed	O
.	O

Finally	O
it	O
caused	O
better	O
BMT	O
and	O
other	O
hematic	O
transplantations	O
(	O
36	O
-	O
38	O
)	O
or	O
even	O
without	O
entering	O
the	O
clinical	O
stage	O
,	O
biological	O
or	O
synthetic	O
structures	O
were	O
used	O
for	O
stem	O
cell	O
proliferation	O
(	O
39	O
-	O
42	O
).	O

In	O
Tan	O
and	O
colleagues	O
research	O
-	O
2011	O
(	O
43	O
),	O
three	O
-	O
dimensional	O
structure	O
was	O
derived	O
from	O
the	O
bone	O
tissue	O
for	O
stem	O
cell	O
proliferation	O
to	O
achieve	O
7	O
.	O
5	O
-	O
fold	O
expansion	O
.	O

In	O
this	O
structure	O
a	O
feeder	O
layer	O
of	O
mesenchymal	O
stem	O
cells	O
was	O
used	O
but	O
scaffolding	O
explanation	O
was	O
not	O
provided	O
so	O
the	O
real	O
significance	O
of	O
this	O
scaffold	O
is	O
the	O
substances	O
that	O
are	O
present	O
.	O

In	O
other	O
studies	O
,	O
non	O
-	O
mineralized	O
bone	O
matrix	O
was	O
used	O
as	O
scaffold	O
.	O

With	O
general	O
comparison	O
of	O
previous	O
research	O
,	O
we	O
want	O
to	O
investigate	O
the	O
applicability	O
and	O
effectiveness	O
of	O
simultaneously	O
using	O
the	O
mineralized	O
scaffold	O
with	O
USSCs	O
feeder	O
layer	O
for	O
proliferation	O
of	O
hematopoietic	O
stem	O
cells	O
(	O
15	O
,	O
17	O
,	O
44	O
-	O
47	O
).	O

The	O
results	O
of	O
our	O
research	O
are	O
also	O
in	O
line	O
with	O
previous	O
studies	O
and	O
showed	O
that	O
proliferation	O
in	O
three	O
-	O
dimensional	O
conditions	O
is	O
better	O
.	O

Kinetics	O
of	O
ex	O
vivo	O
expansion	O
of	O
CD34	B-GP
+	O
cells	O
by	O
flow	O
cytometry	O
in	O
different	O
culture	O
conditions	O
after	O
21	O
days	O
.	O

The	O
results	O
are	O
expressed	O
as	O
mean	O
fold	O
±	O
SD	O
for	O
S2D	O
,	O
F2D	O
,	O
MBA	O
and	O
DBM	O
.	O
P	O
-	O
value	O
compare	O
to	O
the	O
S2D	O
for	O
each	O
condition	O
was	O
significant	O

Kinetics	O
of	O
colony	O
formation	O
of	O
CB	O
-	O
CD34	B-GP
+	O
cells	O
expanded	O
on	O
USSC	O
.	O

CFC	O
counts	O
were	O
performed	O
from	O
the	O
expanding	O
cultures	O
at	O
days	O
0	O
A	O
)	O
and	O
14	O
B	O
)	O

Karyotype	O
of	O
the	O
expanded	O
CD34	B-GP
+	O
cells	O
after	O
21	O
days	O
in	O
3D	O
condition	O
.	O

Chromosome	O
number	O
is	O
46	O
like	O
a	O
normal	O
cell	O
and	O
no	O
fusion	O
between	O
stromal	O
and	O
HSCs	O
in	O
cytogenetic	O
term	O
were	O
obtained	O

b	O

In	O
order	O
to	O
improve	O
efficiency	O
of	O
the	O
tissue	O
and	O
cell	O
culture	O
in	O
tissue	O
engineering	O
,	O
we	O
need	O
to	O
create	O
three	O
-	O
dimensional	O
ex	O
vivo	O
conditions	O
that	O
mimic	O
inside	O
of	O
body	O
(	O
in	O
vivo	O
).	O

For	O
this	O
purpose	O
,	O
the	O
cells	O
are	O
cultured	O
on	O
the	O
suitable	O
scaffolds	O
.	O

To	O
achieve	O
this	O
goal	O
,	O
we	O
need	O
to	O
mimic	O
the	O
inside	O
of	O
body	O
which	O
contains	O
co	O
-	O
culture	O
of	O
purpose	O
cells	O
with	O
the	O
stromal	O
cells	O
simultaneously	O
(	O
51	O
,	O
52	O
).	O

MNCs	O
cannot	O
form	O
colonies	O
in	O
the	O
culture	O
without	O
supportive	O
environment	O
(	O
53	O
).	O

As	O
described	O
above	O
the	O
only	O
difference	O
between	O
DBM	O
and	O
MBA	O
is	O
the	O
lack	O
of	O
mineral	O
in	O
DBM	O
.	O

We	O
know	O
that	O
bone	O
marrow	O
is	O
composed	O
of	O
a	O
protein	O
matrix	O
and	O
a	O
mineral	O
section	O
necessary	O
for	O
hardness	O
,	O
rigidity	O
and	O
stability	O
that	O
enables	O
the	O
skeleton	O
to	O
resist	O
gravitational	O
and	O
mechanical	O
loading	O
,	O
also	O
has	O
the	O
ability	O
to	O
transfer	O
specific	O
signals	O
to	O
stimulate	O
cell	O
division	O
of	O
stem	O
cells	O
.	O

Features	O
of	O
these	O
two	O
scaffolds	O
are	O
similar	O
to	O
bone	O
tissue	O
and	O
were	O
used	O
for	O
bone	O
tissue	O
engineering	O
(	O
54	O
).	O

Three	O
-	O
dimensional	O
geometry	O
and	O
topography	O
of	O
these	O
porous	O
scaffolds	O
with	O
the	O
adherent	O
stromal	O
cells	O
(	O
USSCs	O
)	O
could	O
emulate	O
the	O
bone	O
marrow	O
microenvironment	O
and	O
hematopoesis	O
(	O
55	O
,	O
56	O
).	O

For	O
HSCs	O
,	O
sticky	O
stromal	O
cells	O
are	O
considered	O
as	O
the	O
co	O
-	O
culture	O
to	O
increase	O
the	O
density	O
of	O
blood	O
cells	O
(	O
57	O
,	O
58	O
).	O

Production	O
of	O
extracellular	O
matrix	O
,	O
hematopoietic	B-GP
cytokine	I-GP
,	O
connection	O
and	O
interaction	O
between	O
molecules	O
could	O
be	O
increased	O
in	O
the	O
small	O
cell	O
area	O
.	O

Therefore	O
DBM	O
and	O
MBA	O
by	O
USSC	O
can	O
be	O
a	O
suitable	O
ex	O
vivo	O
mimicry	O
niche	O
by	O
intensifying	O
surface	O
/	O
volume	O
ratio	O
(	O
59	O
)	O
and	O
supporting	O
the	O
stem	O
cell	O
differentiation	O
and	O
expansion	O
.	O

Finally	O
,	O
the	O
production	O
of	O
nutrient	O
materials	O
,	O
growth	O
factors	O
,	O
hormones	O
,	O
autocrine	O
,	O
paracrine	O
,	O
and	O
exocrine	O
(	O
60	O
)	O
factors	O
will	O
be	O
maximum	O
just	O
in	O
the	O
small	O
location	O
called	O
local	O
concentrations	O
of	O
factors	O
(	O
61	O
).	O

Stromal	O
cells	O
are	O
a	O
source	O
of	O
adhesion	B-GP
molecules	I-GP
and	O
growth	O
factors	O
for	O
supporting	O
stem	O
cell	O
expansion	O
(	O
62	O
).	O

USSCs	O
in	O
contrast	O
to	O
the	O
mesenchymal	O
stem	O
cells	O
have	O
the	O
longer	O
telomerase	O
that	O
cause	O
more	O
expansion	O
capacity	O
and	O
self	O
-	O
renewal	O
in	O
these	O
cells	O
.	O

USSC	O
can	O
produce	O
a	O
lot	O
of	O
cytokines	B-GP
such	O
as	O
CSF	B-GP
,	O
LIF	B-GP
(	O
Leukemia	B-GP
Inhibitory	I-GP
Factor	I-GP
),	O
TGF	B-GP
-	I-GP
1β	I-GP
(	O
Transforming	B-GP
Growth	I-GP
Factor	I-GP
-	I-GP
1	I-GP
beta	I-GP
),	O
VEGF	B-GP
(	O
Vascular	B-GP
Endothelial	I-GP
Growth	I-GP
Factor	I-GP
),	O
GM	B-GP
-	I-GP
CSF	I-GP
,	O
M	B-GP
-	I-GP
CSF	I-GP
,	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
IL	B-GP
-	I-GP
11	I-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
IL	B-GP
-	I-GP
15	I-GP
,	O
SDF	B-GP
-	I-GP
1α	I-GP
(	O
Stromal	B-GP
Derived	I-GP
Factor	I-GP
-	I-GP
1	I-GP
alpha	I-GP
)	O
(	O
56	O
).	O

When	O
feeder	O
cells	O
are	O
in	O
contact	O
with	O
the	O
environment	O
in	O
three	O
dimensions	O
,	O
the	O
result	O
is	O
increased	O
secretion	O
of	O
factors	O
that	O
can	O
improve	O
the	O
efficiency	O
of	O
the	O
feeder	O
.	O

Therefore	O
focus	O
on	O
three	O
factors	O
increased	O
secretion	O
and	O
this	O
effect	O
is	O
direct	O
contact	O
of	O
the	O
humeral	O
(	O
61	O
).	O

The	O
scaffold	O
was	O
a	O
6	O
-	O
8mm	O
sided	O
cube	O
and	O
porosity	O
was	O
40	O
%	O
so	O
every	O
aspect	O
of	O
the	O
six	O
-	O
way	O
area	O
scaffold	O
was	O
68	O
.	O
6mm2	O
{(	O
7	O
×	O
7	O
)+	O
0	O
.	O
4	O
×(	O
7	O
×	O
7	O
)}.	O

With	O
regard	O
to	O
the	O
sixth	O
aspect	O
,	O
the	O
general	O
area	O
of	O
​​	O
the	O
scaffold	O
was	O
411	O
.	O
6mm2	O
.	O

The	O
well	O
’	O
s	O
diagonal	O
of	O
each	O
48	O
-	O
well	O
plate	O
was	O
12mm	O
therefore	O
well	O
area	O
was	O
113	O
.	O
04	O
mm2	O
.	O

Finally	O
for	O
MBA	O
and	O
DBM	O
the	O
general	O
surface	O
was	O
524	O
.	O
64mm2	O
that	O
was	O
4	O
.	O
64	O
-	O
fold	O
of	O
S2D	O
.	O

Conclusion	O

Stem	O
cells	O
in	O
the	O
body	O
depends	O
on	O
the	O
three	O
-	O
dimensional	O
mode	O
will	O
be	O
simulate	O
to	O
differentiate	O
or	O
prolife	O
state	O
.	O

Their	O
power	O
of	O
proliferation	O
cannot	O
survive	O
for	O
long	O
outside	O
of	O
niche	O
(	O
63	O
).	O

Niche	O
could	O
control	O
the	O
number	O
of	O
stem	O
cells	O
in	O
the	O
body	O
and	O
prevent	O
them	O
from	O
multiplying	O
too	O
(	O
12	O
).	O

Stem	O
cell	O
expansion	O
out	O
of	O
the	O
niche	O
such	O
as	O
in	O
2D	O
culture	O
or	O
even	O
in	O
the	O
erythropoesis	O
Dexter	O
culture	O
with	O
abnormal	O
face	O
,	O
or	O
uncontrolled	O
proliferation	O
can	O
lead	O
to	O
aneuploidy	O
and	O
cancer	B-DS
.	O

HSCs	O
niche	O
has	O
helper	O
cells	O
with	O
basic	O
materials	O
.	O

This	O
background	O
material	O
or	O
extracellular	O
matrix	O
has	O
a	O
lot	O
of	O
proteins	O
such	O
as	O
fibronectin	B-GP
(	O
64	O
),	O
collagen	B-GP
(	O
65	O
-	O
66	O
)	O
and	O
gelatin	O
(	O
67	O
)	O
that	O
were	O
synthesized	O
for	O
a	O
lot	O
of	O
scaffolds	O
based	O
on	O
them	O
(	O
68	O
).	O

Acid	O
extraction	O
removes	O
the	O
minerals	O
thus	O
the	O
protein	O
surface	O
of	O
the	O
scaffold	O
(	O
flexible	O
microenvironment	O
)	O
is	O
presented	O
which	O
is	O
familiar	O
for	O
the	O
cells	O
.	O

Therefore	O
DBM	O
will	O
be	O
so	O
soft	O
,	O
porous	O
and	O
spongy	O
(	O
45	O
)	O
and	O
the	O
rate	O
of	O
cytokine	B-GP
production	O
and	O
ex	O
vivo	O
hematopoiesis	O
-	O
supporting	O
activity	O
of	O
UCB	O
-	O
derived	O
USSC	O
in	O
3D	O
culture	O
is	O
improved	O
.	O

This	O
is	O
therefore	O
suggested	O
for	O
better	O
3D	O
culture	O
results	O
in	O
tissue	O
engineering	O
.	O

This	O
result	O
shows	O
that	O
multiline	O
age	O
expansion	O
of	O
CD34	B-GP
derived	O
UCB	O
is	O
feasible	O
in	O
the	O
feeder	O
contact	O
cultures	O
without	O
further	O
addition	O
of	O
cytokines	B-GP
.	O

